LY3039478 + Dexamethasone + Placebo
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T-cell Acute Lymphoblastic Leukemia
Conditions
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
Trial Timeline
Oct 1, 2015 → Jan 15, 2018
NCT ID
NCT02518113About LY3039478 + Dexamethasone + Placebo
LY3039478 + Dexamethasone + Placebo is a phase 1/2 stage product being developed by Eli Lilly for T-cell Acute Lymphoblastic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02518113. Target conditions include T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma.
What happened to similar drugs?
5 of 10 similar drugs in T-cell Acute Lymphoblastic Leukemia were approved
Approved (5) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02518113 | Phase 1/2 | Completed |
Competing Products
20 competing products in T-cell Acute Lymphoblastic Leukemia